Janssen-话题@MedSci

#Janssen#

13篇内容 | 1048人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1527095, encodeId=40ce152e09542, content=<a href='/topic/show?id=ad4410248b5' target=_blank style='color:#2F92EE;'>#Janssen#</a>, objectTitle=Janssen的遗传性视网膜疾病基因疗法AAV-RPGR，获得欧洲药品管理局PRIME称号, objectType=article, longId=189502, objectId=3dc618950238, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3dc618950238, replyNumber=0, likeNumber=53, createdTime=2020-03-08, rootId=0, userName=zhang92564, userId=c0ca11798386, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3dc618950238, moduleTitle=Janssen的遗传性视网膜疾病基因疗法AAV-RPGR，获得欧洲药品管理局PRIME称号, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3dc618950238)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527094, encodeId=29b1152e09436, content=<a href='/topic/show?id=ad4410248b5' target=_blank style='color:#2F92EE;'>#Janssen#</a>, objectTitle=Janssen宣布其IL-12/IL-23单抗Stelara治疗克罗恩病的III期中期分析阳性结果, objectType=article, longId=188168, objectId=b557188168d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b557188168d1, replyNumber=0, likeNumber=66, createdTime=2020-02-17, rootId=0, userName=zhang92564, userId=c0ca11798386, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b557188168d1, moduleTitle=Janssen宣布其IL-12/IL-23单抗Stelara治疗克罗恩病的III期中期分析阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b557188168d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527093, encodeId=b04d152e093a3, content=<a href='/topic/show?id=ad4410248b5' target=_blank style='color:#2F92EE;'>#Janssen#</a>, objectTitle=Janssen宣布FDA授予其PARP抑制剂Niraparib治疗转移性去势抵抗性前列腺癌的突破性疗法指定, objectType=article, longId=180512, objectId=112b180512c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=112b180512c6, replyNumber=0, likeNumber=86, createdTime=2019-10-06, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=112b180512c6, moduleTitle=Janssen宣布FDA授予其PARP抑制剂Niraparib治疗转移性去势抵抗性前列腺癌的突破性疗法指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=112b180512c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527092, encodeId=968d152e0927d, content=<a href='/topic/show?id=ad4410248b5' target=_blank style='color:#2F92EE;'>#Janssen#</a>, objectTitle=Janssen的呼吸道合胞病毒RSV疫苗被FDA授予突破性疗法指定, objectType=article, longId=178985, objectId=41461e898555, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41461e898555, replyNumber=0, likeNumber=66, createdTime=2019-09-07, rootId=0, userName=zhang92564, userId=c0ca11798386, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41461e898555, moduleTitle=Janssen的呼吸道合胞病毒RSV疫苗被FDA授予突破性疗法指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=41461e898555)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527091, encodeId=5576152e091e3, content=<a href='/topic/show?id=ad4410248b5' target=_blank style='color:#2F92EE;'>#Janssen#</a>, objectTitle=2019 ASCO：Janssen抗CD38单抗Darzalex治疗多发性骨髓瘤III期数据喜人, objectType=article, longId=167615, objectId=3d4d16e61584, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d4d16e61584, replyNumber=0, likeNumber=68, createdTime=2019-06-05, rootId=0, userName=zhang92564, userId=c0ca11798386, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d4d16e61584, moduleTitle=2019 ASCO：Janssen抗CD38单抗Darzalex治疗多发性骨髓瘤III期数据喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d4d16e61584)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527090, encodeId=a060152e09073, content=<a href='/topic/show?id=ad4410248b5' target=_blank style='color:#2F92EE;'>#Janssen#</a>, objectTitle=美国批准Janssen的艾滋病毒药物Symtuza, objectType=article, longId=144729, objectId=c6d9144e2955, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c6d9144e2955, replyNumber=0, likeNumber=72, createdTime=2018-07-20, rootId=0, userName=zhang92564, userId=c0ca11798386, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c6d9144e2955, moduleTitle=美国批准Janssen的艾滋病毒药物Symtuza, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c6d9144e2955)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527089, encodeId=4c41152e08917, content=<a href='/topic/show?id=ad4410248b5' target=_blank style='color:#2F92EE;'>#Janssen#</a>, objectTitle=Janssen启动了Crohn''s药物Tremfya的PhII / III期计划, objectType=article, longId=144189, objectId=f0e314418910, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0e314418910, replyNumber=0, likeNumber=64, createdTime=2018-07-13, rootId=0, userName=zhang92564, userId=c0ca11798386, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0e314418910, moduleTitle=Janssen启动了Crohn''s药物Tremfya的PhII / III期计划, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0e314418910)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527088, encodeId=34e2152e088b8, content=<a href='/topic/show?id=ad4410248b5' target=_blank style='color:#2F92EE;'>#Janssen#</a>, objectTitle=Janssen的esketamine在治疗难治性抑郁症中的第三阶段成功, objectType=article, longId=141134, objectId=88a6141134f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=88a6141134f2, replyNumber=0, likeNumber=65, createdTime=2018-06-21, rootId=0, userName=zhang92564, userId=c0ca11798386, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=88a6141134f2, moduleTitle=Janssen的esketamine在治疗难治性抑郁症中的第三阶段成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=88a6141134f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527087, encodeId=b302152e08778, content=<a href='/topic/show?id=ad4410248b5' target=_blank style='color:#2F92EE;'>#Janssen#</a>, objectTitle=NHS支持Janssen的Tremfya的使用, objectType=article, longId=137955, objectId=1cd213e9559f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1cd213e9559f, replyNumber=0, likeNumber=48, createdTime=2018-05-13, rootId=0, userName=zhang92564, userId=c0ca11798386, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1cd213e9559f, moduleTitle=NHS支持Janssen的Tremfya的使用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1cd213e9559f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527086, encodeId=abb9152e08616, content=<a href='/topic/show?id=ad4410248b5' target=_blank style='color:#2F92EE;'>#Janssen#</a>, objectTitle=Janssen收购BeneVir Biopharm以推进免疫治疗方案, objectType=article, longId=137195, objectId=7b7713e1954a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b7713e1954a, replyNumber=0, likeNumber=62, createdTime=2018-05-05, rootId=0, userName=zhang92564, userId=c0ca11798386, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b7713e1954a, moduleTitle=Janssen收购BeneVir Biopharm以推进免疫治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b7713e1954a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527085, encodeId=f256152e085ac, content=<a href='/topic/show?id=ad4410248b5' target=_blank style='color:#2F92EE;'>#Janssen#</a>, objectTitle=Janssen的Imbruvica最终被纳入NHS, objectType=article, longId=128592, objectId=60f6128592c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=60f6128592c9, replyNumber=0, likeNumber=82, createdTime=2018-02-03, rootId=0, userName=zhang92564, userId=c0ca11798386, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=60f6128592c9, moduleTitle=Janssen的Imbruvica最终被纳入NHS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=60f6128592c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527084, encodeId=0e87152e0841a, content=<a href='/topic/show?id=ad4410248b5' target=_blank style='color:#2F92EE;'>#Janssen#</a>, objectTitle=Janssen购买了Legend的CART疗法, objectType=article, longId=124469, objectId=742d1244691a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=742d1244691a, replyNumber=0, likeNumber=74, createdTime=2017-12-26, rootId=0, userName=zhang92564, userId=c0ca11798386, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=742d1244691a, moduleTitle=Janssen购买了Legend的CART疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=742d1244691a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527083, encodeId=8030152e08395, content=<a href='/topic/show?id=ad4410248b5' target=_blank style='color:#2F92EE;'>#Janssen#</a>, objectTitle=英国推出Janssen的新型银屑病生物制剂Tremfya, objectType=article, longId=121472, objectId=ec8c1214e24c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec8c1214e24c, replyNumber=0, likeNumber=73, createdTime=2017-11-28, rootId=0, userName=zhang92564, userId=c0ca11798386, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec8c1214e24c, moduleTitle=英国推出Janssen的新型银屑病生物制剂Tremfya, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec8c1214e24c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Janssen

2020-05-29

zhang92564 (审核中...)

前往app查看评论内容

#Janssen#

Janssen的遗传性视网膜疾病基因疗法AAV-RPGR，获得欧洲药品管理局PRIME称号

2020-03-08

zhang92564 (审核中...)

前往app查看评论内容

#Janssen#

Janssen宣布其IL-12/IL-23单抗Stelara治疗克罗恩病的III期中期分析阳性结果

2020-02-17

hb2008ye (审核中...)

前往app查看评论内容

#Janssen#

Janssen宣布FDA授予其PARP抑制剂Niraparib治疗转移性去势抵抗性前列腺癌的突破性疗法指定

2019-10-06

zhang92564 (审核中...)

前往app查看评论内容

#Janssen#

Janssen的呼吸道合胞病毒RSV疫苗被FDA授予突破性疗法指定

2019-09-07

zhang92564 (审核中...)

前往app查看评论内容

#Janssen#

2019 ASCO：Janssen抗CD38单抗Darzalex治疗多发性骨髓瘤III期数据喜人

2019-06-05

zhang92564 (审核中...)

前往app查看评论内容

#Janssen#

美国批准Janssen的艾滋病毒药物Symtuza

2018-07-20

zhang92564 (审核中...)

前往app查看评论内容

#Janssen#

Janssen启动了Crohn''s药物Tremfya的PhII / III期计划

2018-07-13

zhang92564 (审核中...)

前往app查看评论内容

#Janssen#

Janssen的esketamine在治疗难治性抑郁症中的第三阶段成功

2018-06-21

zhang92564 (审核中...)

前往app查看评论内容

#Janssen#

NHS支持Janssen的Tremfya的使用

2018-05-13

zhang92564 (审核中...)

前往app查看评论内容

#Janssen#

Janssen收购BeneVir Biopharm以推进免疫治疗方案

2018-05-05

zhang92564 (审核中...)

前往app查看评论内容

#Janssen#

Janssen的Imbruvica最终被纳入NHS

2018-02-03

zhang92564 (审核中...)

前往app查看评论内容

#Janssen#

Janssen购买了Legend的CART疗法

2017-12-26

zhang92564 (审核中...)

前往app查看评论内容

#Janssen#

英国推出Janssen的新型银屑病生物制剂Tremfya

2017-11-28

科室
- - 订阅+
  - 更多科室
工具
服务